HD-Tdcs and Pharmacological Intervention For Delirium In Critical Patients With COVID-19 (COVID-19)
HD-Tdcs Associated With The Use Of Dexmedetomidine For Delirium In Critical Patients With Covid-19
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Paraiba
-
João Pessoa, Paraiba, Brazil, 51051900
- Federal University of Paraíba
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age ≥18 years,
- confirmed clinical diagnosis for SARS-CoV-2,
- delirium confirmed through the CAM-ICU-7 test, applied by trained evaluators
Exclusion Criteria:
- severe psychiatric illness that is not well controlled;
- pregnancy or active lactation,
- refusal of consent
- contraindications for brain stimulation such as: aneurysm clips, pacemaker, epilepsy, dermatitis at the site of stimulation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active HD-tDCS
HD-tDCS is delivered on 10 consecutive weekdays, with two sessions per day (in the morning and in the afternoon).
For each participant, a 3-mA current is applied via a center anode.
The electric current was supplied to the active group and presented an acceleration time of 30 s, maintained at 3 mA for 30 min and then reduced for 30 s.
And a maintenance dosage of dexmedetomidine (0.2 - 0.7 mcg/kg per hour).
|
Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
|
|
Placebo Comparator: Sham HD-tDCS
HD-tDCS is delivered on 10 consecutive weekdays, with two sessions per day (in the morning and in the afternoon).
For the simulated condition, the investigators maintained the same 30-second acceleration up to a total of 3 mA, followed immediately by a 30-second deceleration.
And a maintenance dosage of dexmedetomidine (0.2 - 0.7 mcg/kg per hour).
|
Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delirium Severity
Time Frame: 28 days
|
delirium severity over the 28-day study period is measured using the CAM-ICU-7.
Patients discharged before 28 days were considered without delirium.
|
28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
length of stay in the ICU and hospital stay
Time Frame: 28 days
|
defined as the total number of days that patients remained in the hospital from the date of randomization to the date of hospital discharge
|
28 days
|
|
Occurrence of hypotension requiring any vasopressor administration
Time Frame: 28 days
|
28 days
|
|
|
C-reactive protein levels
Time Frame: 28 days
|
28 days
|
|
|
ventilator-free days during the first 28 days
Time Frame: 28 days
|
defined as the number of days free from mechanical ventilation for at least 48 consecutive hours
|
28 days
|
|
Exploratory analisys
Time Frame: 28 days
|
Organ dysfunction and clinical response; use of Concomitant Medications; Richmond Agitation Sedation Scale (RASS) and mortality prognosis
|
28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Neurologic Manifestations
- Confusion
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Disease Attributes
- COVID-19
- Delirium
- Critical Illness
Other Study ID Numbers
Other Study ID Numbers
- Delirium/HD-tDCS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.